ABSTRACT The availability of multicopy plasmid vectors for the yeast Saccharomyces cereviiae allows the selective amplification of individual segments of the genome. Increased dosage of particular genes results in overproduction of specific gene products and thereby confers resistance to certain metabolic inhibitors. Advantage was taken of this fact to isolate recombinant clones that increase the activities of the enzymes UDP-N-acetylglucosamine-i-P transferase and 3-hydroxy-3-methylglutaryl-CoA reductase.
The isolation of recombinant clones of specific yeast genes has been aided extensively by various applications of genetic complementation. Several yeast genes have been isolated by their ability to complement mutations in bacterial genes that encode functionally homologous products (1) (2) (3) . However, cloning genes by complementation has achieved its widest currency through the development of yeast transformation (4, 5) and recombinant libraries constructed in vectors capable of autonomous replication in yeast. Many yeast genes have been identified by transforming a mutant yeast strain with a recombinant library, followed by screening or selecting for clones that complement the mutation of interest (reviewed in ref. 6 ). This approach has been widely used and suffers from few limitations. The only significant disadvantages of the approach are the requirement for a mutation in the gene of interest and for a genetic marker that can be used to select for transformation. Even though Saccharomyces cerevisiae is a premier organism for eukaryotic biochemical genetics, only a small fraction of the genes encoding enzymes has been identified by mutation (7) . In addition, there are several known examples of two or more yeast genes encoding either the same product or functionally homologous products or multiple coding sequences for the same product [e.g., carbamoyl phosphate synthetase (8) , asparagine synthetase (9) , a-factor (10), S-adenosylmethionine (AdoMet) synthetase (11) , alcohol dehydrogenase (12) , and glyceraldehyde-3-phosphate dehydrogenase (13) ]. The biology of yeast is sufficiently understood that recessive mutations can be recovered even in duplicated genes such as these. Generally; however, it is difficult to isolate recessive mutations in duplicated genes. In this paper we present an alternative approach for isolating genes whose products are sensitive to specific inhibitors; this method relieves the requirement for complementable mutations in the gene of interest. We use this approach to clone genes involved in three unrelated biosynthetic pathways.
The principle of cloning by exploitation of gene dosage effects is based upon the fact that, generally, increasing the number of copies of a given gene leads to increased synthesis of the products of that gene. The validity of this premise is documented by the fact that segmental aneuploidy has been used in Drosophila genetics as a general mapping technique. The essence of this technique is that the gene for any activity can be mapped by systematically measuring the relative differences in activity in strains containing either a duplication or a deletion for a chromosomal region, segment by segment (14, 15) .
In the yeast S. cerevisiae a large collection of duplications and deficiencies does not exist. Nevertheless it is possible to construct strains that are highly aneuploid, containing many copies of discrete regions of the genome, by using plasmid vec- (20) . Since The TunR Gene Controls Activity of UDP-N-acetylglucosamine-i-P Transferase. Tunicamycin is a specific inhibitor of the first step in the synthesis of N-linked oligosaccharide (i.e., the transfer of N-acetylglucosamine-1-P from UDP-GlcNAc to dolichol-P) (29) . To determine whether resistance to tunicamycin was due to higher levels of UDP-N-acetylglucosamine-1-P transferase or to some unexpected effect of a different plasmid encoded gene, we assayed the enzyme levels of the transferase in two different strains containing the plasmid and in isogenic strains that had lost the plasmid. The results shown in Table 3 indicate that the specific activity of the transferase was increased approximately 8- plasmid-encoded gene. Restriction maps of the four clones indicate that all four share some restriction fragments and various amounts of flanking DNA. Therefore, these clones represent four independent isolations of the same gene (data not shown).
Overproduction of HMG-CoA Reductase. We performed enzyme assays on cell extracts to determine whether resistance to compactin results from overproduction of HMG-CoA reductase activity. Several strains were assayed: (i) JRY117, a strain containing a plasmid that confers resistance to compactin, grown in the presence of compactin; (ii) JRY117 with the same plasmid grown in the absence of compactin; (iii) a derivative of JRY117 that had lost the plasmid, grown in the absence of compactin; and (iv) two other compactin-resistant clones and isogenic compactin-sensitive derivaties. The data in Table 4 demonstrate that the specific activity of HMG-CoA reductase is elevated 7-to 14-fold in strains containing the plasmid. Furthermore, the substantial reduction of activity in extracts from cells grown in the presence of compactin indicates that yeast HMG-CoA reductase is in fact compactin sensitive. As yet, it is unclear whether compactin irreversibly inhibits the yeast enzyme or we simply failed to dilute the extract sufficiently to relieve the inhibition.
Isolation of Clones Conferring Ethionine Resistance. Ethionine, a methionine analog, is a potent inhibitor of AdoMet (33) . In the case of the TunR clones, we isolated the same gene four independent times from a total of 4,000 yeast transformants. From this result we conclude that a relatively small number of transformants is sufficient to screen the entire genome for a given phenotype and that a small number of genes and perhaps a single gene can lead to TunR under these conditions.
The mechanism for the increase in resistance to tunicamycin of cells containing the plasmids pJR39, pJR40, pJR41, or pJR50 by pregrowth in the presence of tunicamycin has not been resolved. Of the possible explanations, we note only two: Tunicamycin may induce the synthesis of the GlcNAc transferase, Biochemistry: Rine et al. Proc . Natl. Acad. Sci. USA 80 (1983) either directly or indirectly. Alternatively, pregrowth in the presence of tunicamycin may select for those cells in which the numerical distribution of recombinant plasmids versus endogenous plasmids favors the recombinant plasmids.
Despite the importance of glycoproteins in cell biology, little is known about either the GlcNAc transferase enzyme or its gene. In related studies we have isolated dominant chromosomal mutations that confer resistance to tunicamycin and increase the activity of this enzyme with no apparent effect on the enzyme's apparent Ki for tunicamycin at the UDP-GlcNAc concentrations used (unpublished observations). It will be of interest to determine whether the clones contain the same genes that are altered by our chromosomal mutations. HMG-CoA reductase is known to be subject to extensive regulation in mammals and is one of the key enzymes targeted in efforts to control hypercholesterolemia (34) . In yeast, relatively little is known about this enzyme or its regulation, even though the end products of this pathway constitute up to 10% of the dry weight of the yeast cell (35) . AdoMet synthetase is a particularly interesting case because there are apparently two unlinked structural genes for this enzyme, both of which must be mutated before a cell becomes an AdoMet auxotroph (11) . The clones that we have isolated have opened several obvious approaches to studies of the biosynthetic pathways of N-linked oligosaccharides and sterols and of the structural and functional relationships of the duplicated AdoMet synthetase genes.
A priori, one would expect the overproduction of certain gene products to be deleterious to the cell. Hence, the genes encoding such products might be impossible to isolate by this procedure. Two pieces of evidence suggest that, in practice, this limitation may not be seen: First, the recombinant plasmids are not evenly distributed between the mother cell and daughter cell during mitotic growth, some cells receiving none of the recombinant plasmids. Since some cells inherit no plasmid, we infer that the ratio of recombinant to endogenous plasmids varies stochastically among different cells within a population. Therefore, even if sufficient overproduction of a particular product kills a cell, within a population there may be cells that contain a sublethal number of recombinant plasmids, and these cells will contribute to the growth of the population. Second, in the transformed cells, the maximal copy number of the recombinant plasmid is limited by its requirement for functions from the endogenous plasmid (16) .
In each of the above experiments, we had a clear idea of which enzyme would most likely be the major target of the inhibitors that we used. The number of yeast enzymes that this approach could be applied to is probably quite large because the Medlars Computer Information Retrieval Service lists well over 1,000 entries under the key words Saccharomyces and growth inhibition. In principle, however, this approach may prove especially valuable in those cases in which the metabolic target of an uncharacterized drug, inhibitor, or noxious influence is unknown. As the number of identified yeast genes and mapped mutations increases, it will become increasingly efficient to establish the identity of genes on plasmids selected by virtue of drug resistance as a first step in the pharmacological characterization of new drugs.
